EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC 3.0

Creatinine Clearance, Ceftazidime-Avibactam Exposure, and Clinical Outcomes in a Real-World TDM Cohort: A Retrospective Observational Study

Bo Yang iD, Jianbiao Meng iD, Bei Zheng, Juan Wang, Nanmei Chen iD, Mingwan Zhang, Chuanwei Xin, Meiling Zhang iD, Yuexing Tu

Drug Design, Development and Therapy · 2026

DOI: 10.2147/dddt.s645493 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Drug Design, Development and Therapy, 2026. Verfasst von Bo Yang und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, Hangzhou, People's Republic of China. Hauptthemen laut MEDLINE: Ceftazidime, Azabicyclo Compounds, Anti-Bacterial Agents, Creatinine. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Ceftazidime-avibactam (CAZ-AVI) is a key option for carbapenem-resistant Enterobacterales (CRE) infections, but whether creatinine clearance (CrCL) independently predicts outcomes or reflects disease severity is unclear. We investigated CrCL, drug exposure, and outcomes in patients with severe Gram-negative infections receiving CAZ-AVI with therapeutic drug monitoring (TDM). Patients and Methods: This retrospective study included 224 patients receiving CAZ-AVI TDM at a tertiary hospital in China (May 2024-May 2025). Three cohorts were defined: trough-concentration (n=224) for factors influencing trough concentrations; concentration-outcome (n=194) for concentration-outcome associations using LASSO; and stable-dose (n=165) for baseline CrCL and outcomes. CrCL was analysed using restricted cubic splines and five prespecified analysis CrCL strata. Multivariable adjustment, E-values, LASSO, and bootstrap-validated ROC were used to separate CrCL from disease severity.

Results

CrCL was the dominant determinant of ceftazidime and avibactam trough concentrations (β = -0.224 and -0.047; q = 0.040 and 0.033, respectively). The unadjusted CrCL-28-day mortality association (OR 0.993, P = 0.030) was attenuated after adjusting for SOFA and APACHE II (OR 0.996, P = 0.285; E-value = 1.07) and after full adjustment (OR 0.996, P = 0.468; E-value = 1.06). LASSO retained SOFA (OR 2.18), CRRT (OR 1.88), age (OR 1.13), and ICU admission (OR 1.03), excluding CrCL. SOFA stratification showed minimal incremental prognostic value for CrCL. The exploratory multivariable model yielded an AUC of 0.760 vs 0.571 for CrCL alone (optimism-corrected AUC: 0.793 vs 0.577).

Conclusion

CrCL drives CAZ-AVI trough-concentration variability but appears to be a marker of disease severity rather than an independent predictor of outcomes. Given the observational design and absence of individual MIC data, these findings should be interpreted cautiously. TDM may be best targeted at patients with extreme pharmacokinetic phenotypes, pending prospective validation. Prospective studies with MIC data are needed to define pathogen-specific targets.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

CeftazidimeAzabicyclo CompoundsAnti-Bacterial AgentsCreatinineDrug MonitoringGram-Negative Bacterial InfectionsHumansRetrospective StudiesDrug CombinationsFemaleMaleMiddle AgedCohort Studies

Stichwörter der Autor:innen

carbapenem-resistant enterobacteralesceftazidime-avibactamcritical carepharmacokinetics/pharmacodynamicsrenal functiontherapeutic drug monitoring

Substanzen

CeftazidimeAzabicyclo Compoundsavibactam, ceftazidime drug combinationDrug CombinationsAnti-Bacterial AgentsCreatinine

Autor:innen und Institutionen

  • Department of Pharmacy, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
  • Department of Critical Care Medicine, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.
  • Department of Clinical Laboratory Science, Tongde Hospital of Zhejiang Province Affiliated to Zhejiang Chinese Medical University, Hangzhou, People's Republic of China.

ORCID-Profile: Bo Yang, Jianbiao Meng, Nanmei Chen, Meiling Zhang

Zitieren

APA

Yang, B., Meng, J., Zheng, B., Wang, J., Chen, N., Zhang, M., Xin, C., Zhang, M., & Tu, Y. (2026). Creatinine Clearance, Ceftazidime-Avibactam Exposure, and Clinical Outcomes in a Real-World TDM Cohort: A Retrospective Observational Study. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s645493

Vancouver

Yang B, Meng J, Zheng B, Wang J, Chen N, Zhang M, et al. Creatinine Clearance, Ceftazidime-Avibactam Exposure, and Clinical Outcomes in a Real-World TDM Cohort: A Retrospective Observational Study. Drug Design, Development and Therapy. 2026. doi:10.2147/dddt.s645493

BibTeX
@article{Yang2026,
  author = {Yang, Bo and Meng, Jianbiao and Zheng, Bei and Wang, Juan and Chen, Nanmei and Zhang, Mingwan and Xin, Chuanwei and Zhang, Meiling and Tu, Yuexing},
  title = {Creatinine Clearance, Ceftazidime-Avibactam Exposure, and Clinical Outcomes in a Real-World TDM Cohort: A Retrospective Observational Study},
  journal = {Drug Design, Development and Therapy},
  year = {2026},
  doi = {10.2147/dddt.s645493}
}
Kostenlos starten →